Opus Genetics is trading 5.73% up in pre-market at $5.24, versus the September 29 close of $4.96; no clear company-specific catalyst for the September 30 move was identified.
- The investor-relations calendar lists a Euretina Innovation Spotlight presentation for September 30, but available sources do not establish that it explains the gain.
- The latest identified major company news was positive Phase 1/2 data announced September 9, not a new overnight announcement.